- Home
- TBI vs URGN Comparison
TBI vs URGN Comparison
Compare TBI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBI
- URGN
- Stock Information
- Founded
- TBI 1985
- URGN 2004
- Country
- TBI United States
- URGN United States
- Employees
- TBI N/A
- URGN N/A
- Industry
- TBI Professional Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- TBI Consumer Discretionary
- URGN Health Care
- Exchange
- TBI Nasdaq
- URGN Nasdaq
- Market Cap
- TBI 169.0M
- URGN 181.2M
- IPO Year
- TBI 1996
- URGN 2017
- Fundamental
- Price
- TBI $6.95
- URGN $14.82
- Analyst Decision
- TBI Buy
- URGN Strong Buy
- Analyst Count
- TBI 1
- URGN 9
- Target Price
- TBI $10.00
- URGN $26.81
- AVG Volume (30 Days)
- TBI 222.0K
- URGN 5.9M
- Earning Date
- TBI 08-04-2025
- URGN 08-12-2025
- Dividend Yield
- TBI N/A
- URGN N/A
- EPS Growth
- TBI N/A
- URGN N/A
- EPS
- TBI N/A
- URGN N/A
- Revenue
- TBI $1,534,794,000.00
- URGN $91,871,000.00
- Revenue This Year
- TBI $0.80
- URGN $36.65
- Revenue Next Year
- TBI $6.90
- URGN $88.35
- P/E Ratio
- TBI N/A
- URGN N/A
- Revenue Growth
- TBI N/A
- URGN 8.98
- 52 Week Low
- TBI $3.45
- URGN $3.42
- 52 Week High
- TBI $12.29
- URGN $18.15
- Technical
- Relative Strength Index (RSI)
- TBI 68.79
- URGN 73.80
- Support Level
- TBI $6.08
- URGN $6.92
- Resistance Level
- TBI $7.35
- URGN $15.22
- Average True Range (ATR)
- TBI 0.36
- URGN 1.57
- MACD
- TBI 0.05
- URGN 1.17
- Stochastic Oscillator
- TBI 85.50
- URGN 96.49
About TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.